• 6133 Citations
  • 39 h-Index
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jordi Rodon is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent, M., Azaro, A., De Vos, F., Sepulveda, J., Yung, W. K. A., Wen, P. Y., Lassman, A. B., Joerger, M., Tabatabai, G., Rodon, J., Tiedt, R., Zhao, S., Kirsilae, T., Cheng, Y., Vicente, S., Balbin, O. A., Zhang, H. & Wick, W., Jan 1 2020, In : Journal of neuro-oncology. 146, 1, p. 79-89 11 p.

Research output: Contribution to journalArticle

Open Access
  • 1 Scopus citations

    A phase I study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer

    Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Ahnert, J. R., Millward, M. J., Zhang, W., Gao, L., Sykes, A., Willard, M. D., Yu, D., Schade, A. E., Crowe, K. A., Flynn, D. L., Kaufman, M. D., Henry, J. R., Peng, S. B., Benhadji, K. A., Conti, I., Gordon, M. S. & 2 others, Tiu, R. V. & Hong, D. S., Feb 2020, In : Molecular cancer therapeutics. 19, 2, p. 460-467 8 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Erratum: Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (Cancer Cell (2019) 36(4) (444–457.e7), (S1535610819303848), (10.1016/j.ccell.2019.09.001))

    Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., Li, S., Chen, T., Han, H., Negrao, M. V., Ahnert, J. R., Diao, L., Wang, J., Le, X., Meric-Bernstam, F., Routbort, M. & 11 others, Roeck, B., Yang, Z., Raymond, V. M., Lanman, R. B., Frampton, G. M., Miller, V. A., Schrock, A. B., Albacker, L. A., Wong, K. K., Cross, J. B. & Heymach, J. V., Mar 16 2020, In : Cancer cell. 37, 3, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • First-in-human phase i study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma

    Wen, P. Y., Cloughesy, T. F., Olivero, A. G., Morrissey, K. M., Wilson, T. R., Lu, X., Mueller, L. U., Coimbra, A. F., Ellingson, B. M., Gerstner, E., Lee, E. Q. & Rodon, J., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1820-1828 9 p.

    Research output: Contribution to journalArticle

    Open Access
  • Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

    Wick, A., Desjardins, A., Suarez, C., Forsyth, P., Gueorguieva, I., Burkholder, T., Cleverly, A. L., Estrem, S. T., Wang, S., Lahn, M. M., Guba, S. C., Capper, D. & Rodon, J., Jan 1 2020, (Accepted/In press) In : Investigational New Drugs.

    Research output: Contribution to journalArticle

    Open Access